Trial Profile
PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Pictrelisib (Primary) ; Taselisib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Lung cancer; Oligodendroglioma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIPA
- 15 Nov 2019 Planned End Date changed from 1 Aug 2017 to 1 Jan 2020.
- 15 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results (n=20) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.